These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25484091)

  • 1. Using BRAF(V600E) as a marker of autophagy dependence in pediatric brain tumors.
    Mulcahy Levy JM; Foreman NK; Thorburn A
    Autophagy; 2014; 10(11):2077-8. PubMed ID: 25484091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors.
    Levy JM; Thompson JC; Griesinger AM; Amani V; Donson AM; Birks DK; Morgan MJ; Mirsky DM; Handler MH; Foreman NK; Thorburn A
    Cancer Discov; 2014 Jul; 4(7):773-80. PubMed ID: 24823863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors.
    Mulcahy Levy JM; Zahedi S; Griesinger AM; Morin A; Davies KD; Aisner DL; Kleinschmidt-DeMasters BK; Fitzwalter BE; Goodall ML; Thorburn J; Amani V; Donson AM; Birks DK; Mirsky DM; Hankinson TC; Handler MH; Green AL; Vibhakar R; Foreman NK; Thorburn A
    Elife; 2017 Jan; 6():. PubMed ID: 28094001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic BRAF inhibitor UAI-201 induces cell cycle arrest and autophagy in BRAF mutant glioma cells.
    Ahn JH; Lee YW; Ahn SK; Lee M
    Life Sci; 2014 May; 104(1-2):38-46. PubMed ID: 24721513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib.
    Idbaih A; Mokhtari K; Emile JF; Galanaud D; Belaid H; de Bernard S; Benameur N; Barlog VC; Psimaras D; Donadieu J; Carpentier C; Martin-Duverneuil N; Haroche J; Feuvret L; Zahr N; Delattre JY; Hoang-Xuan K
    Neurology; 2014 Oct; 83(16):1478-80. PubMed ID: 25209580
    [No Abstract]   [Full Text] [Related]  

  • 6. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF
    Martin S; Dudek-Peric AM; Garg AD; Roose H; Demirsoy S; Van Eygen S; Mertens F; Vangheluwe P; Vankelecom H; Agostinis P
    Autophagy; 2017 Sep; 13(9):1512-1527. PubMed ID: 28722539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells.
    Sueda T; Sakai D; Kawamoto K; Konno M; Nishida N; Koseki J; Colvin H; Takahashi H; Haraguchi N; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Satoh T; Doki Y; Mori M; Ishii H
    Sci Rep; 2016 Jan; 6():18949. PubMed ID: 26750638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib.
    Goodall ML; Wang T; Martin KR; Kortus MG; Kauffman AL; Trent JM; Gately S; MacKeigan JP
    Autophagy; 2014 Jun; 10(6):1120-36. PubMed ID: 24879157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autophagy sustains mitochondrial respiration and determines resistance to BRAF
    Díaz-Gago S; Vicente-Gutiérrez J; Ruiz-Rodríguez JM; Calafell J; Álvarez-Álvarez A; Lasa M; Chiloeches A; Baquero P
    Autophagy; 2024 Jun; 20(6):1383-1397. PubMed ID: 38436206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
    Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF V600E-dependent role of autophagy in uveal melanoma.
    Zhao Y; Wang W; Min I; Wyrwas B; Moore M; Zarnegar R; Fahey TJ
    J Cancer Res Clin Oncol; 2017 Mar; 143(3):447-455. PubMed ID: 27928645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual inhibition of BRAF and mTOR in
    Sen S; Tanaka R; Khatua S; Zaky W; Janku F; Penas-Prado M; Weathers SP; Behrang A; Roszik J; Subbiah V
    Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32843426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vemurafenib.
    Garbe C; Abusaif S; Eigentler TK
    Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilomyxoid astrocytoma treated successfully with vemurafenib.
    Skrypek M; Foreman N; Guillaume D; Moertel C
    Pediatr Blood Cancer; 2014 Nov; 61(11):2099-100. PubMed ID: 24821190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of early-stage autophagy inhibition in BRAF
    Zahedi S; Fitzwalter BE; Morin A; Grob S; Desmarais M; Nellan A; Green AL; Vibhakar R; Hankinson TC; Foreman NK; Mulcahy Levy JM
    Cell Death Dis; 2019 Sep; 10(9):679. PubMed ID: 31515514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib.
    Krayem M; Journe F; Wiedig M; Morandini R; Sales F; Awada A; Ghanem G
    Eur J Cancer; 2014 May; 50(7):1310-20. PubMed ID: 24559688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
    Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
    Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
    Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
    Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.